Ustekinumab safe, effective over 5-year maintenance period

Ustekinumab safely maintained a long-term clinical response and remission in patients with Crohn’s disease and ulcerative colitis, according to a presentation at the American College of Gastroenterology Virtual Annual Scientific Meeting.“By way of background, ustekinumab (UST) is approved for the treatment of moderately to severely active Crohn’s disease and ulcerative colitis,” William J. Sandborn, MD, University of California, San Diego, said. “UST induced and maintained remission in patients in the induction, maintenance and 3-year trials of the UNITI program.”Read More

Share on facebook
Share on twitter
Share on linkedin